Predictive Payer Coverage Solutions: Enabling Clients to Hit the Ground Running Policy Reporter’s goal is to improve patient access to life-changing therapeutics, devices, and diagnostics through a proven, vetted, and collaborative process of payer intelligence and advocacy. Our clients have access to real-time policy, coverage, and prior authorization data that’s proven to enhance market access strategies. […]
Immunology to Oncology: A Study of Biosimilar Market Evolution In the second edition of Policy Reporter’s Biosimilar Market Insights Publication Series: Immunology to Oncology: A Study of Biosimilar Market Evolution, we delve into the dynamics of the oncology market. What lessons did oncology biosimilar manufacturers learn from the launch of infliximab? How did reference product […]
Insights into the Market for Infliximab Products In Policy Reporter’s new Biosimilar Market Insights Publication Series, we provide critical insights into the US biosimilar landscape to help drive your biosimilar strategy. Through a synthesis of proprietary and public data, our first edition analyzes the market for infliximab (Remicade® and its biosimilar competitors) to discuss potential […]
MORRISVILLE, NC—Policy Reporter, a TrialCard-owned medical policy tracking platform for physicians, health plans, laboratories, and product manufacturers, has over the past week alerted its clients to dozens of new and updated payer policies related to the COVID-19 virus. Many of these new policies include the elimination of patient cost-sharing expense for COVID-19 testing, in line […]
We use our own and third parties cookies to improve your experience and our services. If you continue browsing, we take that to mean that you accept their uses and information.